Hostname: page-component-5cf477f64f-h6p2m Total loading time: 0 Render date: 2025-04-02T11:25:43.802Z Has data issue: false hasContentIssue false
  • English
  • Français

Efficacy and Tolerability of Moclobemide Compared with Imipramine in Depressive Disorder (DSM-III): An Austrian Double-blind, Multicentre Study∗

Published online by Cambridge University Press:  06 August 2018

U. Baumhackl ,
K. Bizière ,
R. Fischbach ,
Ch. Geretsegger ,
G. Hebenstreit ,
E. Radmayr  and
M. Stabl
U. Baumhackl
Affiliation:
A. Ö. Krankenhaus St Pölten, Abteilung für Neurologie und Psychiatrie, Pölten, Austria
K. Bizière
Affiliation:
F. Hoffmann-La Roche Ltd, Basel, Switzerland
R. Fischbach
Affiliation:
Landes-Nervenklinik, Neurologie Abteilung, Salzburg, Austria
Ch. Geretsegger
Affiliation:
Landes-Nervenklinik, Psych. Krankenabteilung, Salzburg, Austria
G. Hebenstreit
Affiliation:
Nö Landeskrankenhaus für Psychologie und Neurologie, Mauer b. Amstetten, Austria
E. Radmayr
Affiliation:
Facharzt für Neurologie, Dornbirn, Austria
M. Stabl
Affiliation:
F. Hoffmann-La Roche Ltd, Basel, Switzerland
Get access Rights & Permissions [Opens in a new window]

Abstract

The antidepressant efficacy, tolerability, and safety of moclobemide, a reversible, monoamine oxidase-A inhibitor, were compared with those of imipramine in parallel groups of patients with a major depressive episode, in a 4-week, multicentre (17 centres), randomised study. A total of 381 patients were randomly allocated to either treatment; they were not required to avoid tyramine-rich foods. Drop-out rates were comparable in both groups at about 17%. Judged primarily on the HRSD, no significant differences in efficacy were observed between the groups, but the number of patients presenting with adverse events, as well as the total number of adverse events, was greater with imipramine. Cardiovascular tolerability was satisfactory and physical examination, body weight, and laboratory values were essentially unaffected in both groups.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 155 , Issue S6: Depression and Reversible Monoamine Oxidase Inhibitors-New Perspectives , October 1989 , pp. 78 - 83
Copyright
Copyright © 1989 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Burgess, C.D. & Mellsop, G.W. (1989) Interaction between moclobemide and oral tyramine in depressed patients. Fundamental Clinical Pharmacology, 3, 47–52.CrossRefGoogle ScholarPubMed
Crane, G.E. (1957) Iproniazid (Marsilid) phosphate, a therapeutic agent for mental disorders and debilitating disease. Psychiatric Research Report, 8, 142–152.Google Scholar
Da Prada, M., Kettler, R., Keller, H.H., et al (1989) Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. Journal of Pharmacology and Experimental Therapeutics, 248 (1), 400–414.Google Scholar
Davidson, J., McLeod, M.N. & Blum, M.R. (1978) Acetylation phenotype, platelet monoamine oxidase inhibitor and the effectiveness of phenelzine in depression. American Journal of Psychiatry, 135, 467–469.Google Scholar
Gieschke, R., Schmid-Burgk, W. & Amrein, R. (1988) Interaction of moclobemide, a new reversible monoamine oxidase inhibitor with oral tyramine. Journal of Neural Transmission, 26 (Suppl.), 97–104.Google ScholarPubMed
Horwitz, D., Lovenberg, W., Engelman, K., et al (1964) Monoamine oxidase inhibitors, tyramine and cheese. Journal of the American Medical Association, 188, 1108–1110.Google Scholar
Kline, N.S. & Cooper, T.B. (1980) Monoamine oxidase inhibitors as antidepressants. In Psychotropic Agents. Part I. Antipsychotics and Antidepressants (eds Hoffmeister, F. & Stille, G.), pp. 369–397. Berlinn: Springer-Verlag.CrossRefGoogle Scholar
Korn, A., Da Prada, M., Raffesberg, W., et al (1988) Tyramine pressor effect in man: studies with moclobemide, a novel, reversible monoamine oxidase inhibitor. Journal of Neural Transmission, 26, 57–71.Google Scholar
Müller, T., Gieschke, R. & Ziegler, W.H. (1988) Blood pressure response to tyramine-enriched meal before and during MAO-inhibition in man: influence of dosage regimen. Journal of Neural Transmission, 26 (Suppl.), 105–114.Google Scholar
Paykel, E.S. (1971) Classification of depressed patients: a cluster analysis derived grouping. British Journal of Psychiatry, 188, 275–288.Google Scholar
Robinson, D.S., Nies, A., Ravaris, C.L., et al (1978) Clinical psychopharmacology of phenelzine: MAO activity and clinical response. In Psychopharmacology: A Generation of Progress (eds Lipton, M.A., DiMascio, A. & Killam, K.F.), pp. 961–973. New York: Raven Press.Google Scholar
West, E.D. & Dally, L.J. (1959) Effects of iproniazid in depressive syndromes. British Medical Journal, i, 1491–1494.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.